SCHEMBL4649481

SCHEMBL4649481

COc1ccccc1-c1oc2ccccc2c(=O)c1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 1.00
CYP3A4 P08684 8/20 1.00
MEN1 O00255 7/20 1.00
KMT2A Q03164 7/20 1.00
HSD17B10 Q99714 6/20 1.00
ALDH1A1 P00352 5/20 1.00
HPGD P15428 4/20 1.00
TSHR P16473 4/20 0.74
CYP2C9 P11712 3/20 0.74
CYP2C19 P33261 3/20 0.74
ALOX15 P16050 4/20 0.74
HTT P42858 2/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
TP53 P04637 6/20 0.67
LMNA P02545 4/20 0.67
MAPT P10636 4/20 0.67
TUBB4A P04350 1/20 0.67
TUBB P07437 1/20 0.67
ADORA3 P0DMS8 1/20 0.67
TUBA3C P0DPH7 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31675993 1.00 KDM4E (1.00) KDM4ECYP3A4MEN1KMT2AHSD17B10
SCHEMBL9665953 0.92 KDM4E (0.84) KDM4ECYP3A4MEN1KMT2AHSD17B10
SCHEMBL4649956 0.89 KDM4E (0.80) KDM4ECYP3A4MEN1KMT2AHSD17B10
SCHEMBL21446879 0.86 KDM4E (0.75) KDM4ECYP3A4MEN1KMT2AHSD17B10
SCHEMBL380906 0.85 KDM4E (1.00) KDM4ECYP3A4MEN1KMT2AHSD17B10
SCHEMBL5138931 0.85 KDM4E (0.74) KDM4ECYP3A4MEN1KMT2AHSD17B10
SCHEMBL17079654 0.85 KDM4E (1.00) KDM4ECYP3A4MEN1KMT2AHSD17B10
SCHEMBL4650094 0.85 KDM4E (0.81) KDM4ECYP3A4MEN1KMT2AHSD17B10
SCHEMBL15619540 0.85 KDM4E (0.77) KDM4ECYP3A4MEN1KMT2AHSD17B10
SCHEMBL5433434 0.85 KDM4E (0.74) KDM4ECYP3A4MEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
CN-119954794-A Flavonol derivative containing benzothiazole, and preparation method and application thereof 贵州大学 2025-05-09 CN disclosed
CN-117624162-A Flavonol derivative containing triazolopyridine and preparation method and application thereof 贵州大学 2024-03-01 CN disclosed
EP-2730431-B1 Rubber composition and tire with rubber containing flavone GOODYEAR TIRE & RUBBER (US) 2017-06-28 EP disclosed
US-9629822-B2 Flavonoid based antiviral targets UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2017-04-25 US disclosed
US-20150209323-A1 FLAVONOID BASED ANTIVIRAL TARGETS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, (US) 2015-07-30 US disclosed
US-20140135433-A1 TIRE WITH RUBBER CONTAINING FLAVONE THE GOODYEAR TIRE & RUBBER COMPANY (US) 2014-05-15 US disclosed
EP-2730431-A1 Rubber composition and tire with rubber containing flavone The Goodyear Tire & Rubber Company (US) 2014-05-14 EP disclosed
WO-2014047551-A1 FLAVONOID BASED ANTIVIRAL TARGETS UNIVERSITY OF CENTER FLORIDA RESEARCH FOUNDATION, INC. (US) 2014-03-27 WO disclosed
WO-2007115181-A2 COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF EASTMAN CHEMICAL COMPANY (US) 2007-10-11 WO disclosed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US disclosed
EP-1391327-A1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2004-02-25 EP disclosed
WO-2003057210-A1 COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID KIMBERLY-CLARK WORLDWIDE, INC. (US) 2003-07-17 WO disclosed
US-20030125264-A1 Methods For Treating Wounds KIMBERLY-CLARK WORLDWIDE, INC. 2003-07-03 US disclosed
US-6555523-B1 Such as 3',4'-diacetoxy-5,6,7-trimethoxyflavone or naringin in the treatment HIV, picornavirus, and/or respiratory virus CASCADE ESTATES LTD. (MU) 2003-04-29 US disclosed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP disclosed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150209323-A1 FLAVONOID BASED ANTIVIRAL TARGETS RBM28, MAVS, HAVCR2 KDM4E 3580/4885CYP3A4 4365/4885MEN1 4825/4885
US-20030125264-A1 Methods For Treating Wounds FGF2, MMP1, FIBP KDM4E 2309/4885CYP3A4 3010/4885MEN1 3867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.